Economic Transformation News

UNC spinoff targets bacterial resistance

The University of North Carolina at Chapel Hill has leveraged research into antibiotics to create startup company Synereca Pharmaceuticals.

Synereca has licensed the rights to research conducted by Scott FSingleton, a professor in the Eshelman School of Pharmacy, that addresses the growing problem of bacterial resistance to antibiotics. Synereca intends to improve existing antibiotics by blocking the enzyme RecA, which is a key factor in antibiotic resistance.

For full article, please click here.